Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

Sponsor
AstraZeneca
Study ID
NCT04532645
Status
Completed

Conditions

  • Ovary Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws

Key Dates

Start date
Jan 7, 2021
Status verified
Sep 2025
Primary completion
Sep 27, 2024
Completion
Sep 27, 2024

Study Design

Enrollment
342 participants (actual)

Arms

  • Arm: Patients with BRCA mutated ovarian cancer
    BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting

Primary Outcome Measure

Progression [ Time Frame: 36 months ]

Related Studies